Testosterone News and Research

Latest Testosterone News and Research

BioSante presents update on LibiGel clinical study at NAMS Annual Meeting

BioSante Pharmaceuticals, Inc. presented a LibiGel clinical study update at the 21st Annual Meeting of The North American Menopause Society (NAMS) on October 8, 2010, with more than 1,000 experts and practitioners in menopause and women's health in attendance.

11 Oct 2010

Auxilium commences dosing in global XIAFLEX phase III program for Peyronie's disease

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that the first subject has been dosed in the global phase III program of XIAFLEX® for the treatment of Peyronie's disease. Peyronie's disease is the development of scar tissue on the penis that can cause the penis to curve during erection, often interfering with or preventing intercourse and resulting in psychological distress or bother for the patient.

11 Oct 2010

CDC, national leaders issue recommendations to standardize testosterone tests

The use of testosterone assays for patient care and research is on the rise as new research links testosterone to a variety of diseases and conditions. Although the assays are heavily used, discrepancies and inaccuracies in measurements resulting from the various assays are widespread.

11 Oct 2010

Abiraterone Phase III clinical data to be presented at ESMO meeting

Attendees at next week's European Society of Medical Oncology (ESMO) meeting in Milan will be presented with top-line Phase III Clinical Trials data on Abiraterone in the treatment of castration-resistant prostate cancer.

8 Oct 2010

Androgen deprivation therapy for prostate cancer associated with structural bone decay

Using novel technology allowing "virtual bone biopsies" researchers have found that a common treatment for prostate cancer called androgen deprivation therapy (ADT) is associated with structural decay of cortical and trabecular bone. The study has been accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

6 Oct 2010

Low level of testosterone increases risk for Alzheimer's disease

Low levels of the male sex hormone, testosterone, in older men is associated with the onset of Alzheimer's disease, according to research by a team that includes a Saint Louis University scientist.

6 Oct 2010

BioSante to present LibiGel clinical trial update at NAMS Annual Meeting

BioSante Pharmaceuticals, Inc. today announced that it will present a LibiGel clinical trial update at the 21st Annual Meeting of The North American Menopause Society (NAMS) being held from October 6-9, 2010 at the Sheraton Chicago Hotel & Towers in Chicago, Illinois.

5 Oct 2010

Merck to appeal against jury verdict in retrial of federal FOSAMAX case

Merck & Co., Inc. today said it will appeal a decision by the U.S. District Court for the Southern District of New York that reduced the jury verdict from $8 million to $1.5 million but denied Merck's request for judgment in its favor or a new trial in the case of Boles v. Merck, a retrial of a federal FOSAMAX case.

5 Oct 2010

FDA grants Type B meeting to review Phase III pivotal efficacy protocols for Androxal

Repros Therapeutics Inc. today announced that the Company has been granted a Type B meeting to be held on November 8, 2010 with the Division of Reproductive and Urologic Products to review the Company's Phase III pivotal efficacy protocols for Androxal in the treatment of secondary hypogonadism. Androxal is an oral drug that normalizes both testosterone and sperm levels.

30 Sep 2010

CPEX Pharmaceuticals initiates reviewing strategic alternatives to maximize shareholder value

CPEX Pharmaceuticals, Inc. today announced that its Board of Directors is continuing its previously announced process to review strategic alternatives to maximize shareholder value. The strategic alternatives the Board of Directors is reviewing include, but are not limited to, a sale, merger or other business combination of CPEX with a third party or a monetization of CPEX's assets including its rights to receive royalties and milestone payments.

30 Sep 2010

Medivation and Astellas commence MDV3100 second Phase 3 clinical trial in advanced prostate cancer

Medivation, Inc. and Astellas Pharma Inc. today announced treatment of the first patient in a second Phase 3 clinical trial of the investigational drug MDV3100, which expands the Phase 3 development of the novel, triple-acting oral androgen receptor antagonist into an earlier-stage patient population. Known as PREVAIL, the trial will evaluate MDV3100 in men with advanced prostate cancer who have not yet received chemotherapy. Initiation of the PREVAIL trial triggers a milestone payment to Medivation under its collaboration agreement with Astellas.

29 Sep 2010

Women who smoke during pregnancy can harm child's motor ability: Study

Women who smoke during pregnancy run the risk of adversely affecting their children's coordination and physical control according to a new study from rebro University, Sweden, published in the Journal of Epidemiology and Community Health.

23 Sep 2010

New study signals hope for treatment of rare neurodegenerative disease

A new study led by St. Jude Children's Research Hospital scientists signals hope for treatment of a neurodegenerative disease and a new model for understanding the mechanism at work in other more common neurodegenerative disorders.

23 Sep 2010

Smoking during pregnancy adversely affects children's coordination and physical control

Women who smoke during pregnancy run the risk of adversely affecting their children's coordination and physical control according to a new study from örebro University, Sweden, published in the Journal of Epidemiology and Community Health.

22 Sep 2010

Calm men preferred by women: Study

According to a new study, women prefer calm men to stressed ones. Researchers at the University of Abertay Dundee in Scotland found that women were more attracted to calm, collected men with lower levels of the stress hormone cortisol coursing through their systems, than men who are chronically stressed. The study was published in the Proceedings of the Royal Society B journal. The researchers also found that there was no clear association between attractiveness and high levels of testosterone as was thought before.

16 Sep 2010

Phase II clinical trial shows GTx-758 reduces serum free testosterone

GTx, Inc. today announced that in a Phase II, open label, pharmacokinetic-pharmacodynamic clinical trial, GTx-758, an oral selective estrogen receptor alpha agonist being developed to treat advanced prostate cancer, suppressed serum total testosterone to castrate levels, increased serum SHBG (sex hormone binding globulin), and markedly reduced serum free testosterone in healthy male volunteers.

15 Sep 2010

Harbor BioSciences releases Apoptone clinical trial data for castration resistant prostate cancer

Harbor BioSciences, Inc. a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today released new positive data from its ongoing Phase I/IIa clinical trial with Apoptone(HE3235) for castration resistant prostate cancer (CRPC) – also referred to as hormone resistant prostate cancer.

15 Sep 2010

Differences between sexes affected by environment during first six months of life

It seems the old nature versus nurture debate can't be won. But a new Northwestern University study of men in the Philippines makes a strong case for nurture's role in male to female differences -- suggesting that rapid weight gain in the first six months of life predicts earlier puberty for boys.

14 Sep 2010

VAP Cholesterol Test can evaluate Polycystic Ovarian Syndrome

Polycystic Ovarian Syndrome, known as PCOS, is a silent and often mysterious disease that plays havoc with a woman's body and increases the risk of serious illness. There is no single test for diagnosing the illness, but a detailed cholesterol profile called the VAP Cholesterol Test, along with diet, exercise and the right medication, is changing how doctors approach PCOS and is dramatically altering patients' lives for the better.

10 Sep 2010

High testosterone levels in CEOs linked to higher rate of dropped deals in negotiating M&As

High testosterone levels in CEOs negotiating mergers and acquisitions are linked to a higher rate of dropped deals and an increase in hostile takeover attempts, according to a new study in the current issue of Management Science, a journal of the Institute for Operations Research and the Management Sciences (INFORMS-).

9 Sep 2010

Testosterone News and Research

Latest Testosterone News and Research

BioSante presents update on LibiGel clinical study at NAMS Annual Meeting

Auxilium commences dosing in global XIAFLEX phase III program for Peyronie's disease

CDC, national leaders issue recommendations to standardize testosterone tests

Abiraterone Phase III clinical data to be presented at ESMO meeting

Androgen deprivation therapy for prostate cancer associated with structural bone decay

Low level of testosterone increases risk for Alzheimer's disease

BioSante to present LibiGel clinical trial update at NAMS Annual Meeting

Merck to appeal against jury verdict in retrial of federal FOSAMAX case

FDA grants Type B meeting to review Phase III pivotal efficacy protocols for Androxal

CPEX Pharmaceuticals initiates reviewing strategic alternatives to maximize shareholder value

Medivation and Astellas commence MDV3100 second Phase 3 clinical trial in advanced prostate cancer

Women who smoke during pregnancy can harm child's motor ability: Study

New study signals hope for treatment of rare neurodegenerative disease

Smoking during pregnancy adversely affects children's coordination and physical control

Calm men preferred by women: Study

Phase II clinical trial shows GTx-758 reduces serum free testosterone

Harbor BioSciences releases Apoptone clinical trial data for castration resistant prostate cancer

Differences between sexes affected by environment during first six months of life

VAP Cholesterol Test can evaluate Polycystic Ovarian Syndrome

High testosterone levels in CEOs linked to higher rate of dropped deals in negotiating M&As

Viva Saliva Book: The ultimate guide to saliva Book preview Download eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Testosterone News and Research

Latest Testosterone News and Research

Viva Saliva Book: The ultimate guide to saliva Book preview Download eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in